Cellectis SA (NASDAQ:CLLS) shares reached a new 52-week high during mid-day trading on Wednesday after Nomura raised their price target on the stock to $73.00. Nomura currently has a buy rating on the stock. Cellectis traded as high as $35.14 and last traded at $35.15, with a volume of 459547 shares. The stock had previously closed at $31.65.
Several other research analysts have also issued reports on CLLS. Zacks Investment Research lowered Cellectis from a “buy” rating to a “hold” rating in a research note on Thursday, November 16th. ValuEngine lowered Cellectis from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Oppenheimer reiterated an “outperform” rating and set a $40.00 price objective on shares of Cellectis in a research note on Thursday, December 28th. Finally, BidaskClub upgraded Cellectis from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $42.67.
Large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. acquired a new stake in shares of Cellectis in the third quarter valued at $517,000. Advisors Asset Management Inc. increased its stake in shares of Cellectis by 1,501.1% in the third quarter. Advisors Asset Management Inc. now owns 22,592 shares of the biotechnology company’s stock valued at $643,000 after buying an additional 21,181 shares in the last quarter. Eqis Capital Management Inc. acquired a new stake in shares of Cellectis in the fourth quarter valued at $748,000. Hudson Bay Capital Management LP acquired a new stake in shares of Cellectis in the fourth quarter valued at $1,166,000. Finally, ARK Investment Management LLC increased its stake in shares of Cellectis by 171.7% in the fourth quarter. ARK Investment Management LLC now owns 44,382 shares of the biotechnology company’s stock valued at $1,294,000 after buying an additional 28,048 shares in the last quarter. Institutional investors own 20.36% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Cellectis (CLLS) Sets New 52-Week High After Analyst Upgrade” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3261694/cellectis-clls-sets-new-52-week-high-after-analyst-upgrade.html.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.